Back to Agenda
Session 5 Track C: Generics and Biosimilars
Session Chair(s)
Loretta Del Bosco
Director, Regulatory Affairs Quality Assurance Operations, AbbVie Corporation, Canada
Gain an overview of generics and biosimilars from a regulator, industry, and industry consultant perspective. The field of generics continues to evolve and Canada is entering into the new era of biosimilars. What are the challenges? What are the opportunities? How are generics and biosimilars different? Hear from subject matter experts on this exciting and sometimes controversial topic.
Speaker(s)
Donald Elrick, PHD
Head, Regulatory Affairs & Commercial Quality, Johnson & Johnson Innovative Medicine, Canada
Speaker
Anne Tomalin, RAC
, Tpireg, A Division of Innomar-Strategies Inc., Canada
Policy in the Development of Generics and Biosimilars in Canada
Agnes Klein, MD
Senior Medical Advisor, Health Canada, Canada
Speaker
Dawn Culp
VP, Regulatory Affairs, Hikma, United States
Speaker
Have an account?